How Recent Shifts Are Rewriting the Story for Pulmonx [Yahoo! Finance]
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: Yahoo! Finance
Although the price target is unchanged, investors are watching closely, as shifting analyst perspectives point to renewed optimism supported by leadership changes and product potential. Stay tuned to discover how the Pulmonx narrative continues to evolve and how you can keep up with future valuation shifts. Stay updated as the Fair Value for Pulmonx shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Pulmonx. What Wall Street Has Been Saying Analyst commentary has reflected both optimism and caution regarding Pulmonx, particularly following recent leadership changes and product developments. The following summarizes perspectives drawn from Lake Street's latest research note. ?? Bullish Takeaways Lake Street maintains a Buy rating on Pulmonx, though it has lowered its price target. The firm continues to view shares as attractive based on strong clinical validation of Zephyr valves and an expanding pipeline.
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Pulmonx (NASDAQ:LUNG) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=LUNG&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- Pulmonx (NASDAQ:LUNG) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- Pulmonx outlines $89M–$90M 2025 guidance with renewed focus on execution and cost discipline [Seeking Alpha]Seeking Alpha
- Pulmonx Corporation (LUNG) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
LUNG
Earnings
- 11/12/25 - Beat
LUNG
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- LUNG's page on the SEC website